This 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+® credit.

This program was supported in part by an educational grant from Amgen Canada.

PLANNING COMMITTEE DISCLOSURES

Planning Committee MemberDisclosures
Jonathan Adachi, MD, FRCPC
Professor
Department of Medicine
McMaster University

Speaker’s Bureau/Honoraria: Amgen, CPD Network, Gilead
Grants/Research/Clinical Trials: Amgen, Radius
Consulting Fees: Osteoporosis Canada, International Osteoporosis Foundation

Jacques Brown, MD, FRCPC
Clinical Professor
Department of Medicine
Laval University

Speaker’s Bureau/Honoraria: Amgen, CPD Network
Grants/Research/Clinical Trials: Mereo BioPharma, Radius Health, Servier
Consulting Fees: Amgen, Gilead, Pfizer, Servier, Ultragenyx

Jeff Habert, MD, CCFP, FCFP
Assistant Professor
Department of Family and Community Medicine
University of Toronto

Speaker’s Bureau/Honoraria: Allergan, Amgen, AstraZeneca, Bausch, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, CPD Network, Eli Lilly, Eisai, HLS, Jazz, Lundbeck, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue, Servier, Sunovion
Consulting Fees: Bausch, CCRN, CHRC, CPD Network, CTC, Master Clinician Alliance, MDBriefcase, Thrombosis Canada

Vivien Brown, MD, CCFP, FCFP, NCMP
Assistant Professor
Faculty of Medicine
University of Toronto
VP North America
Medical Women's International Association

Speaker’s Bureau/Honoraria: Amgen, Biosyent, CPD Network, Eisai, GSK, Merck, Moderna, Pfizer, Novartis, Novo Nordisk, Searchlight, Sunovion

Christine Palmay, MD, CCFP
Family Physician
Midtown Health and Wellness Clinic
Toronto, ON

Speaker’s Bureau/Honoraria: Allergan, AstraZeneca, Bayer, Bausch, CPD Network, Galderma, GSK, Lundbeck, Novartis, Nuvo Pharmaceuticals, Valeant
Consulting Fees: Eisai, MD Briefcase, PeerVoice, The Rounds, Sunovion


Learning Objectives

By the end of the program participants will be able to:

  • Describe the mechanisms of action of various treatment options for osteoporosis and how they relate to both specific patients and long-term treatment
  • Summarize data around treatment interruption and long-term use of treatments for osteoporosis
  • Discuss the impact of imminent risk on treatment decisions
  • Assess which types of patients should not interrupt osteoporosis treatment based on fracture risk
Please register or login in order to access this content

cpdisup